Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association最新文献

{"title":"Obesity and Diabetes.","authors":"Jens Aberle, Anne Lautenbach, Svenja Meyhöfer, Markus Menzen, Lars Selig, Knut Mai, Matthias Blüher, Christoph Terkamp","doi":"10.1055/a-2766-3375","DOIUrl":"10.1055/a-2766-3375","url":null,"abstract":"","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"317-325"},"PeriodicalIF":1.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148038707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Projection of Medicine-Treated Type 2 Diabetes in Greece (2016-2022): Real-World Data from the National prescription database.","authors":"Spyros Polyzois, Panagiota Mitrou, Anastasios Tsolakidis, Nikolaos Papanas, Theodoros Constantinides, Christos Kontogiorgis","doi":"10.1055/a-2937-5128","DOIUrl":"https://doi.org/10.1055/a-2937-5128","url":null,"abstract":"<p><strong>Abstract: </strong>Aims: Since type 2 diabetes is one of the greatest burdens in public health over the past decade, evidence regarding its impact on the Greek population is scarce. To address this situation, the current study aims to reveal epidemiological data on type 2 diabetes in Greece by calculating the annual prevalence between 2016 and 2022 and to investigate trends regarding age and sex factors.</p><p><strong>Abstract: </strong>Methods: Real-world prescription data were used from the official database of the e-Government Center for Social Security Services. The study population comprised individuals who were entitled to type 2 diabetes care, with the relevant International Classification of Diseases, 10th Revision code. Descriptive statistics, chi-square tests and regression analysis were performed by calculating prevalence rates, using 2011 official census of Greek population.</p><p><strong>Abstract: </strong>Results: Prevalence rates of type 2 diabetes follow an increasing trend, increasing from 7.97% in 2016 to 8.65% in 2022. A similar trend was observed among male and female individuals; the male prevalence rate increased from 8% in 2016 to 8.86% in 2022, whereas the female prevalence rate increased from 7.95% in 2016 to 8.46% in 2022. The prevalence rate ratios between 2016 and 2022 underline the increasing trends of type 2 diabetes in population, as the total prevalence rate ratio was equal to 1.09 (95% confidence interval: 1.08-1.09, <i>p </i>< 0.001). Linear regression revealed the association between the prevalence rate and the sex or age factor.</p><p><strong>Abstract: </strong>Conclusions: Type 2 diabetes prevalence in Greece increased between 2016 and 2022, in accordance with the European and International data, with higher rates observed among males and older adults. The marked relative increase among individuals aged 18 to 29 years constitutes an important epidemiological finding and highlights the need for targeted prevention and early intervention strategies.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148914748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the clinical characteristics of new onset Graves' disease before and during the Coronavirus disease 2019 era.","authors":"Senem Boz Aksoy, Serhat Özçelik, Naile Gokkaya, Mithat Bıyıklı, Müge Yılmaz, Ece Seçgin Demir, Meryem Özoğlu, Kadriye Aydin","doi":"10.1055/a-2942-6271","DOIUrl":"https://doi.org/10.1055/a-2942-6271","url":null,"abstract":"<p><strong>Abstract: </strong>INTRODUCTION: The aim of this study was to compare the clinical, biochemical, and disease control characteristics of newly diagnosed Graves' disease (GD) before and during the coronavirus disease 2019 (COVID-19) era.</p><p><strong>Abstract: </strong>METHODS: In this retrospective, single-center observational study, 95 patients with newly diagnosed GD between January 2015 and November 2024 were evaluated for thyroid function, autoantibody levels, antithyroid drug (ATD) doses, and disease control status. Patients diagnosed before January 2019 were classified as the pre-COVID-19 group (<i>n</i>=46), whereas those diagnosed after March 2020 were classified as the COVID-19 era group (<i>n</i>=49); patients diagnosed between January 2019 and March 2020 were excluded due to potential classification ambiguity. Only patients treated with ATD for at least 12 months were included in the analysis.</p><p><strong>Abstract: </strong>RESULTS: Patients diagnosed during the COVID-19 era had higher thyroglobulin antibody (TgAb) titers at diagnosis (<i>p</i>=0.001) and higher free thyroxine levels at 12 months and at the final visit (<i>p</i>=0.001). Although the time to euthyroidism was lower in the COVID-19 era group, the difference was not statistically significant. End-of-treatment thyrotropin receptor antibody (TRAb) levels were similar between groups; however, fewer patients in the COVID-19 era group achieved TRAb normalization. Disease control rates and time to achieve disease control under ATD therapy were comparable between the two groups. Among patients diagnosed during the COVID-19 era, 89.8% received at least one messenger RNA vaccine dose, and 40.8% had a positive polymerase chain reaction test.</p><p><strong>Abstract: </strong>CONCLUSION: The COVID-19 era was not associated with a major change in the overall clinical course of GD . However, patients diagnosed during the COVID-19 era had higher TgAb levels at diagnosis and incomplete TRAb normalization in some cases, suggesting subtle differences in thyroid immuneactivity.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148914803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skeletal Muscle Decorin, Apelin and TRIM72 Gene Expression in Relation to Insulin Sensitivity.","authors":"Dominika Szutko, Marek Straczkowski","doi":"10.1055/a-2937-4910","DOIUrl":"10.1055/a-2937-4910","url":null,"abstract":"<p><strong>Abstract: </strong>INTRODUCTION: Skeletal muscle is an essential tissue for insulin-stimulated glucose uptake. Myokines are proteins, peptides, and other metabolites that are released by muscles and exhibit metabolic functions. Decorin, apelin and <i>TRIM72</i> are myokines with connection to an insulin action. The aim of this article was to study the expression of these selected myokines in skeletal muscle in relation to insulin sensitivity in individuals without overt metabolic disturbances.</p><p><strong>Abstract: </strong>METHODS: Thirty healthy young male volunteers with normal glucose tolerance, 14 normal-weight, 8 with overweight and 8 with obesity, were included in the study population. The vastus lateralis muscle biopsies were performed. Insulin sensitivity was tested with hyperinsulinemic-euglycemic clamp. Muscle tissue messenger RNA expression was assessed via a quantitative polymerase chain reaction.</p><p><strong>Abstract: </strong>RESULTS: Group consisting of individuals with obesity had lower insulin sensitivity compared to those with normal weight and overweight. Apelin expression was significantly higher in the obese group compared to the normal-weight and overweight groups. All myokines' expressions correlated with insulin sensitivity: decorin - positively and apelin and <i>TRIM72</i> - negatively. Only apelin was correlated positively with body mass index. Apelin was correlated with insulin sensitivity independently of body mass index, decorin was also correlated with insulin sensitivity independently of body mass index.</p><p><strong>Abstract: </strong>CONCLUSION: Apelin, decorin and <i>TRIM72</i> are correlated with insulin sensitivity and decorin and apelin have body mass index-independent associations. This suggests that these molecules can be linked to metabolic health.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148803597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effects of matrix metalloproteinase-14 Inhibition on diabetic Wound Healing.","authors":"Gui-Feng Zeng, Guotian Chen, Zhen Zhou, Hui-Guang Chen, Guo-Ping Zhang, Shui-Lan Zou, Ziyan Yuan, De-Hong Pan, Hai-Yang Zhou, Gui-Qing Wang, Da-Wei Zhang, Xiao-Dan Xia","doi":"10.1055/a-2943-8604","DOIUrl":"10.1055/a-2943-8604","url":null,"abstract":"<p><strong>Abstract: </strong>Matrix metalloproteinases play critical roles in wound repair, yet their context-dependent functions in diabetic wound healing remain elusive. In this study, we found that both the expression and activity of matrix metalloproteinase-14 were significantly elevated in diabetic foot ulcers. Using animal models, we further revealed the dual roles of matrix metalloproteinase-14 in wound healing. In normal rats, inhibition of matrix metalloproteinase-14 delayed wound closure, confirming its supportive role in physiological tissue repair. In contrast, in diabetic rats, pathologically increased matrix metalloproteinase-14 levels impaired healing, whereas moderate inhibition significantly accelerated wound repair. Among the inhibitors tested, the selective matrix metalloproteinase-14 inhibitor NSC405020 produced the most favorable therapeutic effect in diabetic wounds, markedly enhancing healing rates and collagen deposition at a concentration of 1 mg/mL. Compared with the broad-spectrum matrix metalloproteinase inhibitor ND336, NSC405020 demonstrated therapeutic safety and comparable efficacy without notable toxicity in a rat model. Collectively, these findings elucidate the context-dependent role of matrix metalloproteinase-14 in wound healing, suggesting that matrix metalloproteinase-14 may be a promising therapeutic target for diabetic wound healing. Therefore, our study provides a theoretical foundation for the development of effective and safe treatments for diabetic wound management.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148803603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impaired Epidermal Renewal and Dermal Collagen Disorganization in a Dehydroepiandrosterone-Induced Mouse Model of Polycystic Ovary Syndrome.","authors":"Özlem Delibaş, Berna Özdenoğlu Kutlu, Serpil Ünver Saraydın","doi":"10.1055/a-2942-6488","DOIUrl":"10.1055/a-2942-6488","url":null,"abstract":"<p><strong>Abstract: </strong>BACKGROUND: Polycystic ovary syndrome is a complex endocrine-metabolic disorder associated with various dermatological manifestations. However, the histomorphological alterations underlying these skin findings remain poorly characterized. This study aimed to investigate skin alterations associated with polycystic ovary syndrome in an experimental mouse model using histochemical staining, morphometric evaluation, and immunofluorescence analysis.</p><p><strong>Abstract: </strong>METHODS: An experimental study was performed using 16 Swiss albino female mice. The polycystic ovary syndrome model was induced by dehydroepiandrosterone (6 mg/100 g body weight; subcutaneous). Model validation was performed using ovarian histology, estrous cycle monitoring, body weight, fasting blood glucose, and the intraperitoneal glucose tolerance test. Skin tissues were evaluated using haematoxylin and eosin staining for epidermal and dermal thicknesses, Masson's trichrome staining for collagen content (quantified with ImageJ), and immunofluorescence staining for Ki-67 and vascular endothelial growth factor immunoreactivity.</p><p><strong>Abstract: </strong>RESULTS: The polycystic ovary syndrome model was successfully validated using histological, reproductive, and metabolic parameters. The epidermal thickness was significantly reduced in the polycystic ovary syndrome group compared with the control group, and the dermal collagen content was also decreased. Ki-67 immunoreactivity appeared reduced in the polycystic ovary syndrome group, suggesting decreased cellular proliferative activity. Vascular endothelial growth factor immunoreactivity showed a similar staining pattern in both groups.</p><p><strong>Abstract: </strong>CONCLUSIONS: Dehydroepiandrosterone-induced polycystic ovary syndrome resulted in significant histological alterations in the skin, including epidermal thinning, reduced proliferative activity, and decreased dermal collagen content. These findings suggest that PCOS-associated skin alterations may be linked to impaired epidermal renewal and disrupted extracellular matrix organization, supporting the concept that polycystic ovary syndrome exerts systemic effects beyond the reproductive organs.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148893200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Missing Piece? Continuous Ketone Monitoring for Safer Sodium-Glucose Cotransporter-2 Inhibitor Use in Type 1 Diabetes.","authors":"Djordje Popovic, Dimitrios Patoulias, Theocharis Koufakis","doi":"10.1055/a-2942-0217","DOIUrl":"https://doi.org/10.1055/a-2942-0217","url":null,"abstract":"","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary recommendations for persons with type 2 diabetes mellitus.","authors":"Thomas Skurk, Anja Bosy-Westphal, Arthur Grünerbel, Stefan Kabisch, Winfried Keuthage, André Kleinridders, Peter Kronsbein, Karsten Müssig, Helmut Nussbaumer, Andreas F H Pfeiffer, Marie-Christine Simon, Astrid Tombek, Katharina S Weber, Diana Rubin","doi":"10.1055/a-2766-3314","DOIUrl":"10.1055/a-2766-3314","url":null,"abstract":"","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"277-293"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between the Weight-adjusted Waist Index and New-onset Hyperuricemia: A National Prospective Cohort Study in Chinese Adults.","authors":"Yuxia Li, Qiwei Fan, Sha Zeng, Fengjiao Ning, Siyou Rao, Xi Mei, Yan Zhang, Huaxia Gan, Jiancheng Wang","doi":"10.1055/a-2867-1074","DOIUrl":"10.1055/a-2867-1074","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore the relationship between the weight-adjusted waist index and new-onset hyperuricemia and examine any possible effect modifiers among the middle-aged and elderly Chinese individuals.</p><p><strong>Methods: </strong>We analyzed data from 6,250 participants in the China Health and Retirement Longitudinal Study. The weight-adjusted waist index was calculated as waist circumference divided by the square root of body weight. The study's primary outcome was the incidence of hyperuricemia, identified by serum uric acid levels of≥417 μmol/L in men and≥357 μmol/L in women during the final assessment.</p><p><strong>Results: </strong>During a median follow-up of 4 years, 550 participants (8.8%) developed hyperuricemia. A significant positive correlation existed between the weight-adjusted waist index and the risk of hyperuricemia (odds ratio per unit increase: 1.18; 95% confidence interval: 1.08-1.30). The risk was notably higher in the upper tertiles of weight-adjusted waist index distribution compared to the lowest (Tertile 2: odds ratio: 1.32, 95% confidence interval: 1.04-1.68; Tertile 3: odds ratio: 1.87, 95% confidence interval: 1.45-2.42). Additionally, participants with hemoglobin A1c levels of≥5.7% exhibited a stronger link between the weight-adjusted waist index and the hyperuricemia risk (odds ratio per unit increase: 1.48; 95% confidence interval: 1.07-2.04) than those with hemoglobin A1c levels of<5.7% (odds ratio: 1.31; 95% confidence interval: 1.02-1.69; <i>P</i> for interaction= 0.01). The weight-adjusted waist index did not exhibit better predictive ability compared with body mass index and waist circumference in the results of receiver operating characteristic curves.</p><p><strong>Conclusions: </strong>Our findings suggest that higher weight-adjusted waist index values are independently associated with an increased risk of hyperuricemia, with a particularly strong association in those with elevated hemoglobin A1c levels. However, its predictive capability was not superior to conventional anthropometric indices.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"295-302"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recovery of the Gonadal Axis in Patients with Prolactinomas.","authors":"Joob Ruben Müller, Sara Nader-Müller, Catharina Bullmann, Leena Shahla, Birgit Harbeck","doi":"10.1055/a-2886-2899","DOIUrl":"10.1055/a-2886-2899","url":null,"abstract":"<p><strong>Abstract: </strong>Prolactinomas are the most common functional pituitary adenomas, leading to an increased secretion of prolactin. The symptoms vary and include symptomatic as well as asymptomatic courses. Symptoms are mainly caused by hyperprolactinemia leading to a suppression of the hypothalamic-pituitary-gonadal axis. For individual therapy, planning the knowledge of influencing factors and disease progression is essential. Our goal was to examine the time period as well as the role of other influencing factors until the hypothalamic-pituitary-gonadal axis is normalized under cabergoline-therapy. We retrospectively analyzed the data of patients who were treated at Amedes in Hamburg between 2013 and 2023 from diagnosis to remission. Among initially 410 patients, 66 patients fulfilled all inclusion criteria. This large discrepancy is due to the fact that many patients had already started therapy with cabergoline before their initial endocrinology consultation. As a result, we lacked relevant information on baseline prolactin levels. Diagnosis of the suppressed hypothalamic-pituitary-gonadal axis was made by measuring diminished serum concentrations of luteinizing hormone (women: follicular phase<2.4 mIU/mL, ovulation phase<14.0 mIU/mL, luteal phase<1.0 mIU/mL, and postmenopause<7.7 mIU/mL; men:<1.7 mIU/mL), follicle stimulating hormone (women: follicular phase<3.5 mIU/mL, ovulation phase<4.7 mIU/mL, luteal phase<1.7 mIU/mL, and postmenopause<25.8 mIU/mL; men<1.5 mIU/mL), estradiol (women:<30.9 pg/mL) or testosterone (men: 20-49 y<2.49 ng/mL, from 50 y<1.93 ng/mL). We examined the average time interval until normalization of these concentrations under cabergoline therapy and assessed whether there was a significant correlation between this time interval and other influencing factors. The mean duration until normalization of the hypothalamic-pituitary-gonadal axis under cabergoline therapy was 82 days. The statistical analysis showed a significant correlation between this duration and initial prolactin levels, as well as gender and age. Thus, patients with higher initial prolactin levels, older patients, and men had longer treatment durations. There was no correlation between time period and adenoma size, cabergoline dosage, comedication and accompanying diseases.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"304-310"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148058932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}